PT-141 Interactions: What the Literature Covers on Alcohol, Caffeine, Food and Other Compounds

What the interaction literature on PT-141 actually contains

PT-141, also called bremelanotide, is a synthetic melanocortin receptor agonist that has been studied mainly in the context of sexual response. The published record on how it behaves alongside other substances is far narrower than the range of questions people ask about it. In the literature surveyed here, the single clearest co-administration experiment is the 2005 Urology report in which researchers gave low doses of intranasal PT-141 together with sildenafil to men with erectile dysfunction and described an enhanced erectile response (PMID 15833522). Broader context comes from a review of melanocortin receptors, melanotropic peptides and penile erection (PMID 17584130), a 2005 compilation of agents then moving through clinical development (PMID 16179960), and a 2025 narrative review of intravenous peptides and amino acids for erectile dysfunction (PMID 40069591). None of those publications reported a controlled study of PT-141 with alcohol, caffeine, or a meal.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any question involving a medicine, supplement, or investigational compound. Nothing below is a verdict on whether any combination is safe, advisable, or effective.

Why the mechanism shapes the interaction questions

Interaction questions for most erectile-dysfunction agents are framed around vascular pharmacology, because phosphodiesterase type 5 inhibitors act peripherally on smooth-muscle relaxation. PT-141 sits in a different pharmacological class. The 2007 review of melanocortin receptors, melanotropic peptides and penile erection described melanocortin receptor signalling as a route to erectile response that operates through melanocortin pathways rather than through the peripheral nitric-oxide mechanism exploited by PDE5 inhibitors (PMID 17584130).

That distinction matters for how researchers reason about combinations. Two agents acting on the same effector pathway raise additive-pharmacodynamics questions; two agents acting on separate pathways raise different ones. The 2025 narrative review of intravenous peptides and amino acids for erectile dysfunction placed peptide approaches alongside conventional options and discussed current applications and future directions in that field (PMID 40069591). Reviews of this type map the landscape; they are not substitutes for dedicated interaction trials.

PT-141 with a PDE5 inhibitor: the one co-administration study

The most direct interaction data in this citation set come from the 2005 Urology publication. The study administered low doses of intranasal PT-141 together with sildenafil to men with erectile dysfunction, and the investigators reported that the combination produced an enhanced erectile response compared with the agents given at those low doses individually (PMID 15833522). Because the doses studied were described as low doses of each agent, findings from that design cannot be extended to full-dose combinations, to other PDE5 inhibitors, or to other routes of administration.

Several features of that work limit how far it travels. It examined men with erectile dysfunction, not a general population; it used an intranasal formulation of PT-141 rather than the injectable presentations discussed elsewhere in the literature; and it measured erectile response, not long-term outcomes. The agent's presence in a 2005 clinical-development compilation reflects the stage the programme had reached at that time rather than any conclusion about combination use (PMID 16179960).

Alcohol and PT-141: what the published record shows

No study in the verified literature for this page examined PT-141 together with alcohol. There is no published trial in this set that measured pharmacokinetics, blood pressure, nausea frequency, or sexual-response endpoints when the two were combined, and none of the four cited publications reported an alcohol arm, an alcohol subgroup, or an alcohol-related analysis (PMID 15833522, PMID 17584130).

Mechanistic reasoning (reasoning, not evidence)

The following is how researchers typically reason about such a gap; it is inference rather than measured data. Alcohol is a central nervous system depressant with known vasodilatory and blood-pressure effects, and PT-141 is described in the melanocortin literature as acting through central pathways relevant to erection (PMID 17584130). On that basis, investigators would expect questions about overlapping central and cardiovascular effects to be the ones worth testing. Whether any such overlap actually occurs, in what direction, and at what magnitude has not been established by a study in this set, and mechanistic plausibility is not a finding.

Caffeine, stimulants and PT-141

The same gap applies to caffeine. None of the cited publications studied caffeine, energy drinks, or other stimulants alongside PT-141, and no caffeine-related endpoint appears in the co-administration study that examined intranasal PT-141 with sildenafil (PMID 15833522).

As mechanistic reasoning only: caffeine is a non-selective phosphodiesterase inhibitor and adenosine receptor antagonist at pharmacological concentrations, which is why the question is raised at all given that the one published PT-141 combination study involved a selective PDE5 inhibitor (PMID 15833522). Dietary caffeine exposure and a therapeutic PDE5 inhibitor dose are not pharmacologically equivalent, and no publication in this set tested whether caffeine modifies any PT-141 endpoint. Treating the sildenafil result as a proxy for caffeine would be an extrapolation that the study design does not support.

Food, fasting and route of administration

Food-effect studies are standard for orally administered drugs, because absorption across the gastrointestinal tract can change with a meal. PT-141 has not been studied as an oral agent in the publications cited here. The 2005 study used an intranasal route (PMID 15833522), while the 2025 narrative review addressed intravenous peptide and amino-acid approaches to erectile dysfunction and their current applications and future directions (PMID 40069591).

The reasoning researchers apply here, again labelled as reasoning rather than data, is that parenteral and transmucosal routes bypass first-pass gastrointestinal absorption, so a classical food effect of the kind measured for oral tablets would not be the expected variable. That does not mean a meal, fasting state, or hydration status has no influence on how a melanocortin agonist is experienced; it means no study in this set measured it. Claims about fasted versus fed administration of PT-141 therefore have no supporting trial in the cited literature.

Other commonly asked combinations

Testosterone and hormonal therapy

No publication in this citation set reported a trial of PT-141 combined with testosterone or other hormonal therapy. The melanocortin review discussed receptor pharmacology and erection rather than endocrine co-treatment (PMID 17584130).

Other peptides and amino acids

The 2025 narrative review surveyed intravenous peptides and amino acids used in the erectile dysfunction space and outlined current applications and future directions for that category (PMID 40069591). A review that catalogues a category is not the same as a trial that combined two of its members; no head-to-head or combination trial of PT-141 with another peptide was reported in the material cited here.

Blood-pressure and cardiovascular medications

No interaction study of PT-141 with antihypertensives, nitrates, or other cardiovascular drugs appears in this citation set. The only combination actually tested was with sildenafil at low doses, and the reported outcome was an enhanced erectile response rather than a cardiovascular endpoint (PMID 15833522).

Interaction questions at a glance

Tolerability in Combination Settings: What Studies Report

Within this citation set, tolerability information tied specifically to a combination comes only from the 2005 co-administration work, in which low doses of intranasal PT-141 and sildenafil were given to men with erectile dysfunction and the reported outcome measure was erectile response (PMID 15833522). The other cited publications are reviews and development summaries rather than trials with their own adverse-event tables: the melanocortin review addressed receptors, melanotropic peptides and penile erection (PMID 17584130), the 2025 review addressed intravenous peptides and amino acids for erectile dysfunction (PMID 40069591), and the 2005 compilation catalogued agents in clinical development (PMID 16179960).

Consequently, no comparative adverse-event breakdown for PT-141 with alcohol, caffeine, or food can be drawn from these sources. Readers evaluating tolerability should consult the full publications and current regulatory labelling for approved bremelanotide products, and discuss any specific situation with a clinician.

Limits of this evidence base

• One tested combination. Only the PT-141 plus sildenafil pairing was examined experimentally in this set, at low doses of each agent and in men with erectile dysfunction (PMID 15833522).
• Route-specific data. The combination study used an intranasal formulation, while the 2025 review discussed intravenous peptide approaches, so findings are not interchangeable across routes (PMID 40069591).
• Reviews are not trials. Mechanistic reviews describe pathways and prior work rather than generating new interaction measurements (PMID 17584130).
• Development listings are snapshots. A 2005 compilation of agents in clinical development reflects programme status at the time of publication (PMID 16179960).
• Absence of evidence is not evidence of absence. No interaction study having been published does not establish that no interaction exists.

References

• Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response (Urology, 2005)
• Gateways to clinical trials (Methods and Findings in Experimental and Clinical Pharmacology, 2005)
• Melanocortin receptors, melanotropic peptides and penile erection (Current Topics in Medicinal Chemistry, 2007)
• Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions (Expert Opinion on Pharmacotherapy, 2025)